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Purpose: To determine the profile of neurodegeneration in Leber hereditary optic neuropathy (LHON).
Methods: We quantitated serum levels of phosphorylated neurofilament heavy chain (pNF-H) in a Brazilian pedigree of
16 affected patients and 59 carriers with LHON, both molecularly characterized as harboring the G to A mutation at
nucleotide 11,778 of the mitochondrial genome. The association of subject characteristics to pNF-H levels was studied
with multiple regression; pNF-H data were square-root transformed to effect normality of distribution of residuals.
Relationships between the square-root of pNF-H and age and sex were investigated within groups with Pearson correlation
and the two-sample t-test. Linear regression was used to assess the difference between groups and to determine if the
relationship of age was different between affected individuals and carriers. Results of plotting pNF-H levels by age
suggested a nonlinear, quadratic association so age squared was used in the statistical analysis. ANCOVA was used to
assess the influence of age and group on pNF-H levels.
Results: In the carrier group, there was a significant correlation of square-root pNF-H (mean=0.24 ng/ml2) with age
(r=0.30, p=0.022) and a stronger correlation with quadratic age (r=0.37, p=0.003). With a higher mean pNF-H (0.33 ng/
ml2) for the affected group, correlations were of similar magnitude, although they were not statistically significant: age
(r=0.22, p=0.42), quadratic age (r=0.22, p=0.45). There was no correlation between age and pNF-H levels (mean=0.34
ng/ml2) in the off-pedigree group: age (r=0.03, p=0.87), quadratic age (r=0.04, p=0.84). There was no difference between
sexes and pNF-H levels in any of the groups (affected, p=0.65; carriers, p=0.19; off-pedigree, p=0.93).
Conclusions: Elevated pNF-H released into the serum of some affected LHON patients may suggest that axonal
degeneration occurs at some point after loss of visual function. Increases in pNF-H levels of carriers with increasing age,
not seen in off-pedigree controls, may suggest subtle subclinical optic nerve degeneration.
Leber  Hereditary  Optic  Neuropathy  (LHON)  usually
presents as a bilateral loss of central vision that typically
progresses over weeks to months without pain, until bilateral
central scotomas, dyschromatopsia, and severe visual loss
remain  [1–3].  The  mean  age  of  onset  is  in  the  mid-20s,
although the range is extremely broad. Initially, the optic disc
may be swollen and the peripapillary retinal nerve fiber layer
edematous, then the optic disc atrophies. A common feature
during  the  acute  phase  of  LHON  is  peripapillary
microangiopathy, which was first described by Leber in 1871
[4]. Histopathology of end-stage autopsied nerves showed
axonal loss [5] that likely limits spontaneous recovery of
vision. The pattern visual evoked potential is affected in the
early  stages  of  LHON  and  becomes  extinguished  at  the
atrophic stage, indicating the loss of function of most retinal
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ganglion cells [6,7]. Nevertheless, electroretinograms remain
normal, suggesting the maintenance of photoreceptor cells,
bipolar cells, and the retinal pigment epithelium [8]. Though
LHON is typically monosymptomatic and does not limit life-
span, in early onset cases (2–4 years) other organ systems are
involved, and are characterized by muscle weakness, general
dystonic rigidity, impaired speech and intelligence and short
stature [9–11].
LHON is the most common mitochondrial disease [12].
Almost 20 years ago, it became the first disorder for which a
point mutation in mitochondrial DNA (mtDNA) was linked
to a maternally inherited human disease [13]. Initial molecular
characterization of LHON revealed a G to A transition at
nucleotide  11,778  in  mtDNA  in  the  gene  specifying  the
NADH  dehydrogenase  subunit  4  (ND4)  of  complex  I,
resulting in an arginine to histidine substitution at amino acid
340 [13]. Since then, approximately 45 other pathogenic point
mutations in human polypeptide-coding mtDNA genes have
been linked to LHON [14]. Still, only three primary mtDNA
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2443mutations (G3460A, G11778A, and T14484C) account for
95% of LHON cases, with the G11778A mutation being the
most common, accounting for 50% of LHON cases [15,16].
Patients with the G11778A mutation in mtDNA have the
poorest visual prognosis.
Currently, there is no effective therapy for LHON [17] or
for  any  other  disease  caused  by  mutated  mtDNA  [18].
Experimental  approaches,  such  as  recoding  mitochondrial
genes  in  the  nuclear  genetic  code  and  directing  them  for
import  into  mitochondria  with  a  targeting  sequence,  have
shown promise in rescuing cultured LHON cells [18–21]. One
of the myriad potential problems in applying such promising
experimental treatments to patients with LHON is that it is
unclear when the degeneration of ganglion cells of the retina
and axons of the optic nerve actually begins and when it
becomes irreversible. Optical coherence tomography studies
have detected thinning of the inferior temporal nerve fiber
layer of the retina in asymptomatic carriers with the LHON
mutation [22,23]. This finding suggests that loss of axons may
occur before the visual loss. If so, then intervention may be
needed before optic disc edema sets in, which is seen in LHON
patients at the time of visual loss. A mouse model of LHON
has shown that axonal and retinal ganglion cell (RGC) loss is
not apparent when the optic nerve head is swollen, but that
this axonal and RGC loss is advanced 6 months later [24].
Since  heavily  phosphorylated  axonal  form  of  the
neurofilament heavy chain (pNF-H) has been shown to be a
prospective marker of neurodegeneration [25], we evaluated
serum pNF-H levels in a large Brazilian pedigree [26,27] to
determine  the  profile  of  axonal  and  RGC  loss  in  LHON
patients  and  asymptomatic  carriers  of  mutated  G11778A
mtDNA.
METHODS
Clinical  evaluation  and  molecular  characterization:  The
families (all from one pedigree) were all recruited from a rural
valley between the cities of Colatina and Santa Teresa, Brazil.
All signed consents and the study was approved of by both the
IRBs of Fed. Univ. of Sao Paulo, Brazil and USC, LA, CA.
There was a separate consent for blood drawing that was then
sent separately and later from Brazil to Los Angeles under the
auspices of Brazilian authorities. Descendants through seven
generations of an Italian female ancestor born in 1861 were
examined  by  a  team  of  international  and  Brazilian
neuroophthalmologists  and  research  scientists.  Clinical
examinations included a visual acuity test measured with the
EDTRS  retro-illuminated  “tumbling  E”  chart  and
ophthalmoscopy  of  the  optic  nerve  head  and  retina.
Abnormalities  of  the  optic  disc  included  optic  atrophy,
microangiopathy or swelling of the optic nerve head. The
diagnosis of LHON was made clinically following complaints
of visual loss in 16 patients, and the presence of G11778A
mtDNA confirmed molecularly from DNA extracted from
white  blood  cells  obtained  from  peripheral  blood.  Also
examined  were  59  carriers  with  the  responsible  mtDNA
mutation, who did not complain of loss of vision. Controls
consisted of the spouses of maternally related individuals
having neither the mtDNA mutation nor any significant visual
problems and male descendents of affected or carrier men.
pNF-H  assay:  Serum  of  G11778A  LHON  carriers  and
patients with LHON from a peripheral blood draw in 2005
were coded to mask patient identity. Prior to analysis samples
were thawed out and then centrifuged at 13,000x g in an
Eppendorf centrifuge to pellet out particulate material. The
pNF-H assay was performed essentially as described by Shaw
and coworkers [28]. Recently, the laboratories of Drs. Shaw
and Petzold have independently described pNF-H capture
ELISAs with excellent correlation between the two methods
[29].  In  brief,  the  assay  was  conducted  using  wells  of
microtiter  plates  coated  overnight  with  100  μl  of  affinity
purified  chicken  pNF-H  capture  antibody  (EnCor
Biotechnology Inc., Gainesville, FL), diluted about 1:40 in
10  ml  0.05  M  carbonate  buffer,  pH  9.5  to  give  a  final
concentration of 1 μg chicken IgG per ml. The antibody and
carbonate  mix  was  decanted  and  the  plates  blocked  with
150 μl of 5% nonfat milk in Tris Buffered Saline (TBS) for 1
h. Each plate was washed with 2% nonfat milk in TBS (10 mM
Tris, 150 mM NaCl, pH=7.5) and 0.1% Tween-20 (pH 7.5).
For storage at 4 °C in a sealed damp box, plates were filled
with 50 μl TBS and 0.1% Tween-20 with 1 mM of sodium
azide added as preservative. After washing, a total of 50 μl
standard or 10 μl serum sample plus 40 μl 2% nonfat milk in
TBS and 0.1% Tween-20 were added in duplicate to the plate.
The plates were incubated on a shaker at room temperature
(RT) for 1 h. After washing, 100 μl affinity purified rabbit
anti-pNF-H antibody, at a final concentration of 1 μg/ml in
2% nonfat milk in TBS plus 0.1% Tween-20, was added to
each well and the plate incubated for 1 h at RT. The microtiter
plate was washed and 100 μl alkaline phosphatase–labeled
goat  anti-rabbit  antibody  (Sigma,  St.  Louis,  MO),  diluted
1:1000 in TBS, was added and incubated for 1 h at RT. After
a final wash, 100 μl pNP phosphatase substrate in 0.1 M
glycine, 1 mM Mg2+, 1 mM Zn2+ at pH 10.4 was added per
well. The plate was incubated with shaking at RT. The assay
showed  low  background,  and  although  usable  data  were
obtained within 15 min, the reactions were allowed to proceed
for 2 h or more. The absorbance was read at a wavelength of
405 nm on a Tecan SpectraFluor ELISA plate reader (Tecan
Group Limited, Durham NC), generally 1 h after addition of
chromogen. The reaction was stopped by adding 50 μl 2M
NaOH per well.
Data  analysis:  Data  analysis  was  performed  using  SPSS
statistical software (Chicago, IL). The association of subject
characteristics to pNF-H levels was studied with multiple
regression. The pNF-H data were square-root transformed to
effect normality of distribution of residuals. Relationships
between the square-root of pNF-H and age and sex were
investigated within groups with Pearson correlation and the
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difference  between  groups  and  to  determine  whether  the
relationship of age was different between affected individuals
and  carriers.  Including  both  the  carrier  and  affected
individuals in the same analysis raised the question of what
age was appropriate. We used the age at time of testing for the
carriers and the age of onset for the affected individuals.
Results of plotting pNF-H levels by age suggested a nonlinear,
quadratic  association,  so  age  squared  was  used  in  the
statistical analysis. ANCOVA was used to assess the influence
of age and group on pNF-H levels.
RESULTS
Clinical profile: The clinical profile of LHON patients is
shown in Table 1. Their average age was 42 years with a range
from 17 to 68 years. The interval between onset of visual loss
and examination ranged from 1 to 33 years, with an average
of 18 years. There was a 7:1 male predominance with 14 men
and two women. The women were the two oldest LHON
patients  studied.  Visual  acuity  was  poor,  ranging  from
counting  fingers  to  hand  movements.  Ophthalmoscopy
revealed optic atrophy in all patients.
The clinical profile of carriers with mutated mtDNA is
shown in Appendix 1. Their average age was 36 years, with a
range  from  8  to  65  years.  There  was  a  2:1  female
predominance  with  40  women and  19  men.  While  visual
acuity ranged from 20/20 to counting fingers, most carriers
had good vision with a mean visual acuity of 0.109 for the
right  eyes  and  0.107  for  the  left  eyes  (ETDRS  logMAR
charts). We found 23 patients had abnormal ophthalmoscopy
with  either  swelling  of  the  nerve  fiber  layer,  hyperemia,
microangiopathy, or pallor of the optic nerve head. There were
17 men and 22 women in the off-pedigree control group. Their
average age was 39 years. They had no ocular diseases.
pNF-H titers: Figure 1 shows plots of square-root pNF-H
(Figure 1A) and pNF-H (Figure 1B) in affected individuals
and carriers by decade of age. In the carrier group there was
a  significant  correlation  of  square-root  pNF-H  with  age
(r=0.30, p=0.022) and a stronger correlation with quadratic
age (r=0.37, p=0.003). Correlations were of similar magnitude
but not statistically significant in the smaller affected group:
age (r=0.22, p=0.42), quadratic age (r=0.22, p=0.45). There
was no correlation between age and pNF-H levels in the off-
pedigree group: age (r=0.03, p=0.87), quadratic age (r=0.04,
p=0.84). There was no difference between sexes in pNF-H
levels in any of the groups (affected, p=0.65; carriers, p=0.19;
off-pedigree, p=0.93)
Quadratic age was significantly correlated with square-
root of pNF-H (p=0.012), and the affected group was elevated
above  the  carrier  group  (p=0.044).  The  association  of
quadratic  age  in  carriers  and  affected  groups  was  not
significantly  different  (p=0.80,  test  of  group  by  age
interaction). This relationship is displayed in Figure 1. Off-
pedigree  individuals  displayed  no  evidence  of  this
relationship, and they had pNF-H measurements that were
comparable to those of affected individuals.
DISCUSSION
We  have  shown  here  that  phosphorylated  neurofilament
heavy chain appears to be a marker of neurodegeneration in
affected  LHON  patients  relative  to  asymptomatic  carriers
with mutated mtDNA. Neurofilaments are major components
of the axonal cytoskeleton that consist of 3 major subunits: a
light (NF-L), medium (NF-M), and heavy (NF-H) chain. They
are released into the bloodstream with axonal disruption, and
TABLE 1. CLINICAL PROFILE OF LHON PATIENTS
Age                              Age                            VA VA Disc Disc
M 38 * CF CF pale pale
M 48 48 CF CF pale pale
M 43 21 CF CF pale pale
M 18 14 CF CF pale pale
M 24 18 CF CF pale pale
M 27 *
F 68 35 CF CF pale pale
F 62 31 HM HM pale pale
M 50 25 CF CF pale pale
M 41 32 CF CF pale pale
M 46 35 CF CF pale pale
M 17 16 CF CF pale pale
M 35 13 CF CF pale pale
M 52 30 HM HM pale pale
M 59 40 CF CF pale pale
M 48 41 CF CF pale pale
The asterisk indicates missing data. This table describes the summary of sex, age at the time of examination, age of onset of
visual loss, visual acuity, and optic disc appearance at the time of examination of LHON patients.
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(examination) (onset) Sex OD OD OS OSthe heavily phosphorylated axonal form of NF-H, pNF-H, has
a collection of unusual properties that render it resistant to
proteases and relatively easy to detect with ELISA and other
antibody-based  assays.  That  the  heavy  chain  breakdown
product was detectable decades after visual loss may suggest
that the optic nerve neurodegeneration of LHON may be a
lifelong process. This is supported by histopathologic and
ultrastructural studies of autopsied LHON patients that show
axons of the optic nerve in various stages of degeneration, in
addition  to  the  virtually  complete  axonal  loss  of  the
papillomacular bundle [5,30]. Unfortunately, here we were
unable  to  obtain  blood  samples  from  patients  when  they
initially lost vision. Still the single sample obtained from a
patient  within  the  first  year  of  visual  loss  revealed
undetectable  levels  of  pNF-H.  This  may  suggest  that
irreversible anatomic axonal injury may not present at the time
of acute visual loss in some LHON patients.
Parallels of our patients with the LHON animal model
reveal the optic disc edema characteristic of acute visual loss
is not immediately associated with any significant loss of
axons or their neuronal cell bodies [24]. These experimental
findings together with the lack of pNF-H elevation in the
single LHON patient examined during the first year of visual
loss suggest that axonal loss in patients with acute LHON and
disc edema has not yet occurred to any significant degree.
Moreover, increased blood levels of pNF-H in some LHON
patients suggest not all axons are lost but a number are still
undergoing degeneration even many years after visual loss.
These findings may suggest the potential of a longer window
of opportunity for therapeutic intervention than is currently
believed.  Still,  it  must  be  pointed  out  that  a  purported
neuroprotectant, brimonidine, was not demonstrated to be
effective in preventing loss of vision even when administered
topically before significant visual loss during the period of
disc edema [17].
The increasing pNF-H blood levels with age of LHON
carriers and reactive oxygen species found in the optic nerve
of the LHON mouse [24] suggest that accumulating oxidative
injury contributes to the neurodegeneration associated with
mutated  mtDNA.  These  findings  point  to  two  potential
avenues  of  intervention  in  the  disease  process.  First,
antioxidant gene therapy may be useful to rescue patients with
LHON from the axonal and neuronal injury responsible for
persistent loss of vision [31]. Though it had no counterpart in
human  disease,  rescue  of  an  animal  model  of  complex  I
deficiency induced by the NDUFA1 ribozyme with a gene that
neutralizes  reactive  oxygen  species  (mitochondrial
superoxide  dismutase)  proved  that  in  that  model  system,
suppression  of  reactive  oxygen  species  inhibited  death  of
retinal ganglion cells, a phenomenon that we showed in the
LHON animal model is also involved in the pathogenesis of
neurodegeneration caused by the mutant human ND4 complex
I subunit gene [24]. Second, complementation of the defective
ND4 subunit gene with the normal ND4 gene holds promise
as an alternate way to treat LHON. We and others have used
allotopic  complementation  with  wild-type  human  ND4  to
rescue cultured LHON cells [19,21]. That allotopic expression
can rescue complex I deficiency in vivo was proven in a
murine  model  of  Parkinson  disease.  Rather  than
complementing the defective 8 kDa complex I subunit [32]
with a human gene, the investigators used the AAV vector to
deliver the single-subunit NADH dehydrogenase (NDI1) of
yeast (Saccharomyces cerevisiae) [33]. Despite the marked
mismatch in the amino acid sequence and size of the yeast
relative to the murine complex I, a 50% rescue of complex I
activity was seen in their mice. They have also used the yeast
NDI1 to rescue complex I deficiency in a mutant ND4 cell line
Figure 1. pNF-H levels versus age. Plots of the square root of pNF-
H (ng/ml2; A) and pNF-H (ng/ml; B) show that pNF-H levels increase
with advancing age of carriers and affected patients but not in the
off-pedigree control group.
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genes from other species, changing the ratio of heteroplasmy
with  specific  restriction  endonucleases,  selecting  for
respiratory function or regeneration (in muscle), none of these
techniques are directly applicable to the treatment of LHON
caused by 100% mutated mtDNA [20,35]. Whether allotopic
complementation or antioxidant gene therapy is effective in
treating or preventing LHON remains to be determined.
In LHON it is unclear when the degeneration of ganglion
cells of the retina and axons of the optic nerve actually begins
and when it becomes irreversible. In other diseases, optical
coherence tomography has revealed loss of axons in optic
neuritis and multiple sclerosis (MS) patients, but could not
detect neurodegeneration until after axons were gone, 3–6
months after acute visual loss [36]. In contrast, serum titers of
pNF-H  have  been  shown  to  be  a  prospective  marker  of
neurodegeneration  in  optic  neuritis  and  multiple  sclerosis
patients  [37–39].  In  those  patients,  elevated  pNF-H  titers
carried a poor visual prognosis as was also the case with our
LHON patients, who had been followed clinically for 5 years
and had exhibited no evidence for visual recovery. Whether
asymptomatic  carriers  with  elevated  pNF-H  titers  will
progress to full blown LHON is unclear. In MS, cerebrospinal
fluid  pNF-H  levels  increased  in  those  with  primary  or
secondary progressive disease, but in those with relapsing
remitting  disease  pNF-H  titers  were  elevated  acutely  and
decreased later [40]. These findings suggest that the patterns
of neurodegeneration differ, even in a single disease such as
MS. This may also be the case for LHON. Currently, the
prognosis for asymptomatic family members with mutated
mtDNA is unclear, despite many studies that have looked for
additional genetic markers and environmental factors [27,41–
43]. It will be intriguing to follow asymptomatic carriers using
the pNF-H assay to determine whether the increases with
advancing age will progress to frank disease or whether the
progression of neurodegeneration in carriers progresses too
slowly to advance beyond the threshold of clinical visual loss
in their lifetime.
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2449Appendix 1. Clinical profile of carriers
To access the data, click or select the words “Appendix
1.” This will initiate the download of a compressed (pdf)
archive that contains the file. The asterisk indicates missing
data. This appendix describes the summary of sex, age at the
time of examination, age of onset of visual loss, visual acuity,
and  optic  disc  appearance  at  the  time  of  examination  of
asymptomatic carriers with G11778A mutated mtDNA.
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